\
&
Contact us
This was 1 year ago
LocationOnline
ProgrammesThe European Cancer Imaging Initiative aims to promote innovation in digital technologies, including Artificial Intelligence, to advance in the fight against cancer. The cornerstone of the initiative is the Cancer Image Europe Infrastructure developed by the Digital Europe project EUCAIM. The platform will make large amounts of cancer images available to European researchers, innovators and clinicians in a privacy-preserving setting, opening the door to the next generation of cancer diagnostics and treatment.
This CONNECT University session will present the Initiative’s milestones and achievements, and delve into EUCAIM’s infrastructure from multiple perspectives. The session will also explore Cancer Image Europe’s approach in working with sensitive health data, as well as current uptake, trends and future horizons for AI-based imaging solutions in cancer.
For more information on the event, the agenda and the connection link please visit the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.